The question the Houston business community must be able to answer today is “Are we going to be ready for 2035?” Photo via Getty Images

In 1914, Winston Churchill faced a difficult decision. Over two decades before his first term as Prime Minister during World War 2, he oversaw the entire Royal Navy as First Lord of the Admiralty. Shipbuilding technology was rapidly evolving in that era and one of the key questions was whether to use coal or oil as fuel for the large ships in the fleet. Coal was the more proven technology at that point and the British had a strong supply chain across the Empire. Oil was lighter and easier to operate, but the worldwide supply and infrastructure were still limited.

Ultimately Churchill was persuaded by Admiral Jacky Fisher and others to convert the entire fleet to oil. To resolve the supply chain issue, the British government bought a majority stake in Anglo-Persian Oil Company, which became BP. The Royal Navy was possibly the largest consumer of fuel worldwide at the time, so this decision had a major effect on the energy transition in that era. Within 30 years, steam engines were no longer used for transportation in most of the world.

In that same decade, Houston emerged as a leading energy hub in the United States: Humble Oil was founded, the Houston Ship Channel was dredged, and the Baytown Refinery was constructed. World War I in Europe, and the mass adoption of cars in the US spurred a major increase in demand for oil. Oil went on to dominate the global energy market, providing cheap and reliable transportation, industrial production, and materials. Houston grew and prospered along with it to become the 5th largest metro area in the country today.

Over a century later, the global energy industry may be at a similar inflection point. According to IEA, the electric vehicle market more than tripled from 4 percent in 2020 to 9 percent in 2021 to 14 percent in 2022. Major automakers like GM, Ford, Volkswagen, Mercedes, and Volvo have pledged to become all-electric by early-to-mid 2030s. Similar commitments are being made in commercial trucking and shipping.

At the same time, the electric power grids in the United States and many other nations are undergoing a rapid shift to renewable energy. Lazard’s annual Levelized Cost of Energy (LCOE) report showed that by 2015, wind and utility-scale solar power in the US were cheaper than all other technologies on a $/MWh basis; the gap has only grown wider since. EIA data on new power generation capacity in the US for 2020-2023 shows that solar, wind, and energy storage combined have ranged from 74 percent to 81 percent while natural gas has ranged from 14 percent to 22 percent and other fuels less than 5 percent.

All of these figures show market trends that are already happening, not projections of what may happen if the technologies improve. This leads to a natural question: will the growth of EVs and renewable energy reach a limit and tail off? Or will this trend continue until the internal combustion engine and fossil fuel power are replaced like steam engines were before? Both EVs and renewable energy are experiencing insatiable market demand in developed markets but have hit other barriers such as supply chain and infrastructure. However, just as the oil industry itself demonstrated in the past, those constraints can be overcome if the push is strong enough.

The year 2035, only 12 years away, is a major deadline for the transition. The US government and the EU have both set it as a target to complete the transition to EVs. In the US electric power industry, BloombergNEF projects that 126 GW of US coal power will retire before then. S&P also forecasts 85 GW of new energy storage will be online, which will help resolve intermittency and transmission issues that have limited the role of renewable energy up to now. That paints a picture of a radically different energy industry from the one we see today; one with oil demand at a fraction of its current levels and natural gas demand in rapid decline as well.

These market trends have drawn a variety of responses in Houston and other energy hubs, ranging from enthusiastic adoption to cautious skepticism to firm denial. Two recent examples of this range are BP CEO Bernard Looney advocating for continued investment in renewable energy and Shell CEO Wael Sawan emphasizing a move away from them due to lower returns. Business leaders should always be aware of threats to their long-term operations, regardless of their personal opinions on an issue. While demand for oil generally remains strong, every business in the energy industry should be prepared for the scenario that all new cars sold in a decade are electric. There is a graveyard of companies like Kodak, Sears, and Blockbuster Video that failed to act on an existential market threat until it was too late.

Plans for the transition can look different from company to company, but Houston is full of resources that can help with planning and deployment. The workforce, financial sector, and professional services can adapt to new energy technologies from their existing oil and gas expertise. Industry organizations like the Houston Energy Transition Initiative, Renewable Energy Alliance Houston, and the energy policy centers at Rice University and the University of Houston can help leaders make connections and discuss new technologies.

The burden is on every business leader to make use of the time remaining, not only to make plans for the changes coming in the energy industry, but to implement those plans. The question the Houston business community must be able to answer today is “Are we going to be ready for 2035?”

------

Drew Philpot is president of Blended Power, a renewable energy consulting practice based in Houston. This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.